Assertio Holdings, Inc. - ASRT STOCK NEWS

Assertio Holdings, Inc. (ASRT) reported a remarkable financial performance for Q4 and the full year 2022. Net product sales soared by 55% in Q4, reaching $49.9 million, and increased 42% for the full year, totaling $155.1 million. The company achieved a net income of $109.6 million, significantly up from a loss in 2021, driven by a substantial tax benefit. Adjusted EBITDA rose 108% to $101.6 million. Cash flow from operations was $26.7 million in Q4. Looking ahead, Assertio projects 2023 net product sales between $150 million and $160 million. The company is strategically focused on expanding its product offerings and enhancing its balance sheet.

Assertio Holdings, Inc. (Nasdaq: ASRT) appointed Dr. Howard J. Franklin as Senior Vice President, Medical, enhancing its leadership team. The company sees substantial opportunities to expand its portfolio, particularly with Indocin, as they prepare for clinical studies planned for 2023. Dr. Franklin’s extensive experience, including previous roles as Chief Medical Officer at Finch Therapeutics and Salix Pharmaceuticals, positions him to develop a comprehensive clinical strategy that leverages Assertio's innovative sales model. The firm aims to create value by expanding addressable markets and acquiring promising assets.

Assertio Holdings, Inc. (NASDAQ: ASRT) has entered into privately negotiated exchange agreements to reduce its 6.50% Convertible Senior Notes due 2027 by $30 million, representing a 42.9% decrease. The transactions will cost the company $10.5 million in cash and will save $2 million in annual interest payments, with an estimated EPS increase of $0.02 in 2023. Approximately 7 million shares of common stock will be issued under these agreements. Upon completion, Assertio will retain $40 million in outstanding notes. The transaction is expected to close on February 27, 2023, under customary conditions.

Assertio Holdings (Nasdaq: ASRT) reported preliminary, unaudited financial results for Q4 and Full Year 2022, highlighting a year-over-year net product sales increase of at least 54% for the fourth quarter and 41% for the full year. The company achieved cash flows from operations of at least $26 million for Q4 and $78 million for the year, reflecting strong commercial execution. Net product sales for Q4 ranged from $49 million to $50 million, while full-year sales ranged from $154 million to $155 million. Assertio will provide more detailed audited results on March 8, 2023.

Assertio Holdings, Inc. (NASDAQ: ASRT), a specialty pharmaceutical company, announced investor meetings scheduled for February 23, 2023, as part of the virtual Third Annual Winter Wonderland Best Ideas Investor Conference. CEO Dan Peisert and CFO Paul Schwichtenberg will host these meetings. Additionally, a group presentation will take place on February 22, 2023, at 9:30 AM ET, accessible via the Investor Relations section on Assertio’s website. For one-on-one meeting scheduling, interested parties can contact the conference hosts via provided email addresses.

Assertio focuses on differentiated pharmaceutical products in neurology, hospital, and pain/inflammation sectors.

Assertio Holdings, Inc. (Nasdaq: ASRT), a specialty pharmaceutical company, announced that CEO Dan Peisert and CFO Paul Schwichtenberg will conduct investor meetings on February 15, 2023, during the SVB Securities Global Biopharma Conference, which will be held virtually.

Investors can schedule one-on-one meetings by contacting their SVB Securities representative or reaching out to Matt Kreps in Investor Relations at Assertio. The company offers a wide range of branded prescription products, focusing on neurology, hospital, and pain and inflammation sectors, and has expanded through licensing, mergers, and acquisitions.

Assertio Holdings, Inc. (Nasdaq: ASRT) announced a $100,000 educational grant to the LGS Foundation to raise awareness about Lennox-Gastaut Syndrome (LGS) and provide educational resources. Assertio recently acquired exclusive rights to SYMPAZAN^® (clobazam) oral film, FDA-approved for treating seizures associated with LGS in patients aged two and older. The company aims to enhance awareness of SYMPAZAN's unique oral film delivery method, which simplifies medication administration for LGS patients. This collaboration signifies Assertio's commitment to improving the lives of those affected by LGS.

Assertio Holdings, Inc. (Nasdaq: ASRT) announced the addition of U.S. Patent No. 11541002 for Sympazan oral film to the FDA's Orange Book, extending patent protection until 2039. This patent is crucial for the treatment of epilepsy with clobazam. The company aims to boost its portfolio through strategic business development, targeting an incremental gross profit increase of $50 million by 2024. Currently, $18 million is secured from recent transactions, including Sympazan. Assertio's focus remains on diversifying its assets and enhancing its market position.

Assertio Holdings announced the grant of restricted stock units (RSUs) and stock options to four newly-hired employees, effective January 3, 2023, totaling 14,804 RSUs and 16,001 options. This initiative, per NASDAQ Listing Rule 5635(c)(4), aims to attract talent. The stock options have an exercise price of $4.17 per share, equal to the company's closing stock price on the grant date, and will vest annually over three years.

Assertio focuses on differentiated pharmaceutical products in neurology, hospital, and pain management.